Table 3.
Effects of flavonoids on components of metabolic syndrome (primary outcomes).
| Flavonoid | BW | BMI | WC | SBP | DBP | LDL-c | HDL-c | TG | TC | BG | IR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anthocyanin | |||||||||||
| Qin et al., 2009 [29] | = | = | = | = | = | ↓ | ↑ | = | = | = | NA |
| Hassellund et al., 2012 [36] | NA | NA | NA | = | = | NA | NA | NA | NA | NA | NA |
| Hassellund et al., 2013 [37] | NA | NA | NA | NA | NA | = | ↑ | = | = | ↑ | = |
| Zhu et al., 2011 [25] | = | = | = | = | = | ↓ | ↑ | = | = | = | = |
| Zhu et al., 2013 [32] | NA | NA | NA | NA | NA | ↓ | ↑ | = | = | NA | NA |
| Zhu et al., 2014 [52] | NA | NA | NA | NA | NA | ↓ | ↑ | = | = | = | = |
| Zhang et al., 2016 [34] | NA | NA | NA | NA | NA | ↓ | ↑ | = | = | NA | NA |
| Thompson et al., 2017 [53] | = | = | = | = | = | = | = | = | NA | = | NA |
| Yang et al., 2020 [24] | NA | NA | NA | NA | NA | = | = | = | = | = | = |
| Xu et al., 2021 [27] | = | = | = | = | = | = | ↑ | = | = | = | = |
| Zhao et al., 2021 [28] | = | = | = | = | = | = | ↑ | = | ↓ | = | = |
| Hesperidin | |||||||||||
| Morand et al., 2011 [42] | = | = | NA | = | ↓ | = | = | = | = | = | = |
| Rizza et al., 2011 [48] | = | = | = | = | = | = | ↑ | = | ↓ | = | ↓ |
| Salden et al., 2016 [38] | = | = | = | ↓ | ↓ | = | = | = | = | = | = |
| Ohara et al., 2016 [35] | = | = | = | NA | NA | ↓ | = | = | ↓ | NA | NA |
| Yari et al., 2020 [50] | = | = | = | ↓ | = | ↓ | = | ↓ | ↓ | ↓ | ↓ |
| Yari et al., 2021 [49] | = | = | = | ↓ | ↓ | NA | = | ↓ | NA | = | = |
| Quercetin | |||||||||||
| Egert et al., 2009 [43] | = | = | = | ↓ | = | = | ↓ | = | = | = | NA |
| Egert et al., 2010 [51] | = | = | = | ↓ | = | ↓ | ↓ | = | = | = | NA |
| Pfeuffer et al., 2013 [26] | = | = | ↓ | ↓ | = | = | ↑ | ↓ | = | = | = |
| Dower et al., 2015 [39] | = | = | NA | = | = | = | = | = | = | = | = |
| Epicatechin | |||||||||||
| Dower et al., 2015 [39] | = | = | NA | = | = | = | = | = | = | = | ↓ |
| Esser et al., 2018 [40] | = | = | NA | = | = | = | = | = | = | ↓ | ↓ |
| Kirch et al., 2018 [44] | = | = | = | = | = | = | = | = | = | = | = |
| Epigallocatechin G. | |||||||||||
| Brown et al., 2009 [46] | = | = | = | = | ↓ | = | = | = | = | = | = |
| Chatree et al., 2021 [45] | = | = | = | ↓ | ↓ | = | = | ↓ | = | = | = |
| Genistein | |||||||||||
| Hodgson et al., 1998 [30] | = | NA | NA | NA | NA | = | = | = | = | NA | NA |
| Guevara-Cruz et al., 2020 [47] | = | = | = | = | = | = | = | = | = | = | ↓ |
| Theaflavins and Catechin | |||||||||||
| Trautwein et al., 2010 [31] | = | = | NA | NA | NA | = | = | = | = | = | NA |
| Eriocitrin, Hesperidin, Naringin, and Didymin | |||||||||||
| Ribeiro et al., 2019 [41] | = | = | NA | ↓ | = | = | = | = | = | ↓ | ↓ |
↓↑, significant augmentation or diminution; NA, not assayed; =, no change; BW, body weight; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; BG, blood glucose; LDL-c and HDL-c, low and high density lipoprotein cholesterol; TG, triglycerides; TC, total cholesterol; IR, insulin resistance.